

APPENDIX

Table of content:

Appendix Table S1 – sg RNA

Appendix Table S2 – primers

Appendix Table S3 – antibodies

Appendix Table S4 – antibodies for flow cytometry analysis

Appendix Table S5- p values for Fig 5 and Fig EV5

Appendix Table S1 - sgRNA

Target	Guide	sgRNA
TCF7 (TCF1)	1	TCGCTCGTGAACGAGTCCGA
	2	ATGCCGCAGCTGGACTCCGG
LEF1	1	CGAGATCAGTCATCCCGAAG
	2	ATGATCCCCTTCAAGGACGA
ZBTB33	1	GCTACAGACATTCACTACTC
	2	AAGCATCTCAGGTACAGCGC

Appendix Table S2 - primers

Application	Target	Primer Forward	Primer Reverse
ChIP-qPCR	CDK12	TGATAAGCAGGGGAATGAGG	CCTCCACACCACACACACTC
	DDX20	ACCAGTTGCCTCATCTTTCC	TGGGAGCGAGAAGAAGAAAA
	RBM39	AAAAGTATCCCATGCCAAG	TCTTTAGGGGTAGGGGGAGA
	RPL10A	TCAGGACTGCGACAACTCTG	AGGACCAACTCACCTCATGG
	POLR1C	GAGACGGAGCAGGGCTACTA	CTCAAGGCCACAAGGCTTAC
	POLR2E	CCTGAATGCAGCAACGTCT	GTGGGAGTTGAACGGAAACT
Expression	CTNNB1/ β -Catenin	CGGAGACGGAGGAAGGTCTG	TCCATCAAATCAGCTTGAGTAGC
	ZBTB33/Kaiso	GTGCGGCTTCTTCTTGTTGG	TCCATGCCCTTTCTCTTTCT
	RPS19	AGACGTGAACCAGCAGGAGT	TTCTCTGACGTCCCCCATAG
	RPL12	CCTGGGTCTGTCTCCAAAAA	GTTCTTGAGGGCTTTGATG
	RPL10A	TGGAGTTGCAGATCAGCTTG	GGCCAAAAACGCATCATACT
	POLR1C	CCAGGCTGATCTCTTTCCAG	TCTGGCAGGAGCCTGTAAC
	MATR3	CGAAGCAGCGTTGGAAAATG	CATCACTTTGACCATCTGCG
	TBP	TGCCCCGAAACGCCGAATATAATC	GTCTGGACTGTTCTTCACTCTTGG
	HPRT1	ATAAGCCAGACTTTGTTGG	ATAGGACTCCAGATGTTTCC

Appendix Table S3 - antibodies

Application	Target	Source	Reference	Host specie	µg or dilution
ChIP	β-Catenin	R&D Systems	AF1329	Goat	2.5 µg
	β-Catenin	Santa Cruz	sc-7199	Rabbit	10 µg
	TCF1/TCF7	Cell Signaling	2206S	Rabbit	1/50
	LEF1	Abcam	ab137872	Rabbit	2.5 µg
	Kaiso	Santa Cruz	sc-23871 X	Mouse	10 µg
	acetyl-Histone H3	Upstate	06-599	Rabbit	5 µg
WB	β-Catenin	BD Biosciences	610154	Mouse	1/1000
	Active-β-Catenin	Millipore	05-665	Mouse	1/1000
	Kaiso	Bethyl Laboratories	A303-558A	Rabbit	1/1000
	TCF1/TCF7	Cell Signaling	2206S	Rabbit	1/1000
	LEF1	Abcam	ab137872	Rabbit	1/1000
	Tubulin	Sigma	T6074	Mouse	1/10000
	Histone H3	Abcam	ab1791	Rabbit	1/10000

Appendix Table S4 – antibodies for flow cytometry analysis

Target	Fluorochrome	Source	Reference	Clone	Target specie	Dilution
CD45	PerCP Cy5.5	Invitrogen	45-0451-82	30-F11	Mouse	1/200
CD45	APC H7	BD Biosciences	560178	2D1	Human	1/200
HLA-ABC	FITC	BD Biosciences	555552	G46-2.6	Human	1/200
CD5	PE	Biolegend	300622	UCHT2	Human	1/200
Ki67	AF647	BD Biosciences	558615	B56	Human	1/100

Appendix Table S5

Figure (panel)	Comparison	p-value	p-value summary	Statistical test	Previous test	p-value (previous test)
Fig 5a	sh β -cat + VCR vs sh control + VCR	0.0004	***	Two-sided Student's t test		
Fig 5b	VCR + DMSO vs VCR + ICG-001 0.5 μ M	0.0025	**	Two-sided Student's t test		
Fig 5b	VCR + DMSO vs VCR + ICG-001 1 μ M	0.0002	***	Two-sided Student's t test		
Fig 5b	VCR + DMSO vs VCR + ICG-001 2.5 μ M	<0.0001	****	Two-sided Student's t test		
Fig 5b	VCR + DMSO vs VCR + ICG-001 10 μ M	<0.0001	****	Two-sided Student's t test		
Fig 5c (left)	MTX + DMSO vs MTX + ICG-001 0.5 μ M	0.6313	n.s.	Two-sided Student's t test		
Fig 5c (left)	MTX + DMSO vs MTX + ICG-001 1 μ M	0.0310	*	Two-sided Student's t test		
Fig 5c (left)	MTX + DMSO vs MTX + ICG-001 2.5 μ M	0.0006	***	Two-sided Student's t test		
Fig 5c (left)	MTX + DMSO vs MTX + ICG-001 10 μ M	0.0208	*	Two-sided Student's t test		
Fig 5c (central)	L-ASP + DMSO vs L-ASP + ICG-001 0.5 μ M	0.0002	***	Two-sided Student's t test		
Fig 5c (central)	L-ASP + DMSO vs L-ASP + ICG-001 1 μ M	<0.0001	****	Two-sided Student's t test		
Fig 5c (central)	L-ASP + DMSO vs L-ASP + ICG-001 2.5 μ M	<0.0001	****	Two-sided Student's t test		
Fig 5c (central)	L-ASP + DMSO vs L-ASP + ICG-001 10 μ M	0.0002	***	Two-sided Student's t test		
Fig 5c (right)	Ara-C + DMSO vs Ara-C + ICG-001 0.5 μ M	0.0063	**	Two-sided Student's t test		
Fig 5c (right)	Ara-C + DMSO vs Ara-C + ICG-001 1 μ M	0.0034	**	Two-sided Student's t test		
Fig 5c (right)	Ara-C + DMSO vs Ara-C + ICG-001 2.5 μ M	0.0022	**	Two-sided Student's t test		
Fig 5c (right)	Ara-C + DMSO vs Ara-C + ICG-001 10 μ M	0.0014	**	Two-sided Student's t test		
Fig 5e (2 days after treatment initiation)	VCR vs untreated	<0.0001	****	Tukey's multiple comparisons test	One-way ANOVA	<0.0001
Fig 5e (2 days after treatment initiation)	VCR + ICG-001 10 μ M vs untreated	<0.0001	****	Tukey's multiple comparisons test	One-way ANOVA	<0.0001
Fig 5e (2 days after treatment initiation)	VCR vs VCR + ICG-001 10 μ M	0.0007	###	Tukey's multiple comparisons test	One-way ANOVA	<0.0001
Fig 5f (3 days from drug wash-out)	VCR 15 nM, recovery in ICG-001 vs recovery in complete medium	<0.0001	****	Two-sided Student's t test		
Fig 5f (8 days from drug wash-out)	VCR 15 nM, recovery in ICG-001 vs recovery in complete medium	0.0006	***	Two-sided Student's t test		
Fig 5f (3 days from drug wash-out)	VCR 15 nM + ICG-001 10 μ M, recovery in ICG-001 vs recovery in complete medium	0.0011	**	Two-sided Student's t test		
Fig 5f (8 days from drug wash-out)	VCR 15 nM + ICG-001 10 μ M, recovery in ICG-001 vs recovery in complete medium	0.0217	*	Two-sided Student's t test		
Fig 5h (0 days after treatment initiation)	sh β -cat untreated vs sh control untreated	0.3554	n.s.	Two-sided Student's t test		
Fig 5h (2 days after treatment initiation)	sh β -cat untreated vs sh control untreated	<0.0001	****	Two-sided Student's t test		
Fig 5h (2 days after treatment initiation)	sh β -cat VCR 1 nM vs sh control 1 nM	<0.0001	####	Two-sided Student's t test		
Fig 5h (2 days after treatment initiation)	sh β -cat VCR 15 nM vs sh control 15 nM	<0.0001	++++	Two-sided Student's t test		
Fig 5i (3 days from drug wash-out)	VCR 1 nM, sh β -cat vs sh control	<0.0001	****	Two-sided Student's t test		
Fig 5i (8 days from drug wash-out)	VCR 1 nM, sh β -cat vs sh control	0.0058	**	Two-sided Student's t test		
Fig 5i (3 days from drug wash-out)	VCR 15 nM, sh β -cat vs sh control	0.0009	***	Two-sided Student's t test		
Fig 5i (8 days from drug wash-out)	VCR 15 nM, sh β -cat vs sh control	<0.0001	****	Two-sided Student's t test		